BONE MINERAL DENSITY IN SJOGREN'S DISEASE
https://doi.org/10.14412/1995-4484-2002-1208
Abstract
Objective. To study mineral density of bone tissue (BMD) in female pts with Sjogren's syndrome (SS) depending on menstrual statute and to evaluate the effect on it of long-term (for 5 years and more) therapy by prednizolone in dosage 2.5-5 mg/day on the state of bone tissue. Material and methods. 120 female pts aged 30-63 were examined by densitometry of low back and femoral neck with «Hologic 1000». Results. Comparison of obtained results with reference base data enabled to reveal negative effect of prednizolo- nc on bone tissue mineralization, clearly demonstrated at the beginning of glucocorticosteroid therapy in peri- menopausa. It was also noted that menopausa began earlier in pts taking prednizolone (at 43.9±5.1 y/o) as compared with untreated ones (at 4S.9±4.5 y/o); there were notable effect of the age of menopausa beginning on BMD and lower effect of the duration of postmenopausa. Rare (3.3%) development of osteoporosis in women of reproductive age associated with long-term non-correctable hypergammaglobulinemia and damage of renal tubular apparatus.
References
1. <div><p>Васильев В.И., Симонова М.В., Сафонова Т.Н. Болезнь Шегрена. Ревматические болезни. Под ред. Насоновой В.А., Бунчука Н.В. М. Медицина, 1997, 196-210.</p><p>Васильев В.И., Симонова М.В. Сафонова Т.Н. Критерии диагноза болезни и синдрома Шегрена. Избранные лекции по клинической ревматологии. Под ред. Насоновой В.А., Бунчука Н.В. М. Медицина, 2001,112-132.</p><p>Насонов ЕЛ., Скрипникова И.А., Беневоленская Л.И,, Насонова В.А. Патогенез остеопороза: анализ иммунологических механизмов. Клин, ревматол., 1996, 3, 2-11.</p><p>Насонов Е.Л., Гукасян Д.А., Насонова М.Б. Иммунопатология ревматоидного артрита и оетеопороз: новые данные. Ос- теопороз и остеопатии, 2000, 2, 4-7.</p><p>Насонов Е.Л., Скринникова И.А., Насонова В.А. Проблема остеопороза в ревматологии. М., “Стин", 1997, 48-61.</p><p>Рожинская Л.Я., МароваЕ.И., Бухман А.И. и др. Минеральная плотность костной ткани при эндогенном и экзогенном гопер- кортицизме. Оетеопороз и остеопатии, 2000, 2, 12-17.</p><p>Сметннк В.П. Системные изменения у женщин в климактерии. РМЖ, 2001, 9 (9),354-358.</p><p>СпиртусТ.В. Распространенность остеопороза и остеопенин в популяционной выборке лиц 50 лет и старше по количественной оценке минеральной плотности костной ткани. Дне. канд. мед. наук. М., 1997, 73-83.</p><p>Франке Ю„ Рунге Г. Оетеопороз. М. ‘'Медицина", 1995,32-40.</p><p>Aasarod К., Haga H.-J., Berg KJ. et al. Renal involvement in primary Sjbgrens syndrome. Q. J Med., 2000, 93,297-304.</p><p>Amft N., Bowman S.J., Cumow J. at al. Chemokine and chemok- ine receptor expressoin determines the pattern of inflammatory cell infiltrates in Sjdgrens syndrome. Rheumatol., 2001, 40, 118-120.</p><p>Ajjan R.A., Macintosh R.S., Waterman E.A. atal. Analysis T-cell receptor Va repertoire and cytokine gene expression in Sj6gren s syndrome. Brit. J. Rheumatol., 1998, 37,179-185.</p><p>Cuello C.v Palladinetti P., Telda N. at al. Chemokine expression and leucocyte infiltration in Sjogren s syndrome. Brit. J. Rheumatol., 1998, 37, 779-783.</p><p>Cluinie G.P.R., Fox Р.Е., Stamp Т.С.В. Four cases of acquired hypophosphalaemic osteomalacia. Problems оГ diagnosis, treatment and long-term managment. Rheumatol.,2000,39, i415-l42L</p><p>Deodhar A.A., WoolC A.D. Bone mass measurement and bone metabolism in rheumatoid arthritis: u review. Br.J.Rheumatol., 1996,35,309-322.</p><p>Devidson B.K.S., Haslock I. Osteomalacia secondary to renal tubular acidosis masquerading as primary biliary cirrosis. Rheumatol., 2000,39,1428-1429.</p><p>Fox R.I. Sjogren,s syndrome: current therapies remain inadequate for a common disease. Expert Opin. Investig. Drugs, 2000,9,20072016.</p><p>Fox R.I. Vth International Symposium on Sjogren’s syndrome. Clinical aspects and therapy. Clin. Rheumatol., 1995, 14, suppl.l, 17-19.</p><p>Hulkkonen J„ Pertovaara М., Antonen J. at al. Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary SjOgrens syndrome and correlate with the clinical manifestations of the disease. Rheumatol., 2001,40, 656-661.</p><p>Laan R.F.J.M., Jansen T L.Th.A., van Riel P.L.C.M. Glucocorti- costeroids in the management of rheumatoid arthritis. Rheumatol., 1999, 38, 6-12.</p><p>Matsumura R., Umemiya K„ GotoT. etal. Glandular and extrag- landular expression of costimulatory molecules in patients with SjOgren’s syndrome. Ann. Rheum. Dis., 2001, 60(May), 473-482.</p><p>Mivawaki S., Nishivama S., Matoba K. Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjogren's syndrome. Intern. Med., 1999, 38(12), 938-943.</p><p>Oelzner P., Hein G. Inflammation and bone metabolism in rheumatoid arthritis. Pathogenetic viewpoints and therapeutic possibilities. Med. Klin., 1997 (Oct). 92(10), 607-614.</p><p>Saag K.G. Emkey R„ Schnitzer T.J. et al. Alendronate for the prevention and treatment оГ glucocorticoid-induced osteoporosis. N. Engl. J. Med., 1998, 339, 292-299.</p><p>Van Staa T.P., Leufkcns H.G.M., Abenhaitn L. at al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatol., 2000, 39, 1383-1389.</p><p>Tobias J.H. Management of steroid-induced osteoporosis: what is the current stale of play? Rheumatol. 1999, 38:198-201.</p><p>Tomas S., Coll J., Palason X. Soluble interlekin-2 receptor in primary and secondary Sjogren’s syndrome. Brit. J. Rheumatol., 1997. 36, 194-197.</p><p>Verthoeven A.C., Boens M. Limited bone loss due corticosteroids; a systematic review of prospective studies in rheumatoid arthritis and other diseases. J.Rheumatol., 1997,24, 1495-1503.</p><p>Vlachoyiannopoulos P.G., Moutsopoulos H.M. Therapy of Sjflgren’s syndrome. Rheumatol., in Europe, 1995, 24 (2), 63-65.</p><p>Wahner H.W., Fogelman I. The evaluation of osteoporosis: Dual energy Х-ruy absorptiometry in clinical practice. Dunitz, 1994,118-193.</p><p>WHO. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group. Geneva: World Health Organization, 1994, 48.</p></div><br />
Review
For citations:
Sliornikova N.S., Vassiliev V.I., Smirnov A.V. BONE MINERAL DENSITY IN SJOGREN'S DISEASE. Rheumatology Science and Practice. 2002;40(3):8-12. (In Russ.) https://doi.org/10.14412/1995-4484-2002-1208
Views:
946
Email this article 